Convergence Investment Partners LLC Boosts Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Convergence Investment Partners LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 53.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,851 shares of the biopharmaceutical company’s stock after buying an additional 10,766 shares during the period. Convergence Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $2,076,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Northwestern Mutual Investment Management Company LLC boosted its position in Halozyme Therapeutics by 0.9% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 26,310 shares of the biopharmaceutical company’s stock valued at $1,771,000 after buying an additional 238 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Halozyme Therapeutics by 19,326.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock worth $5,753,000 after buying an additional 85,036 shares during the period. Arbejdsmarkedets Tillaegspension purchased a new stake in Halozyme Therapeutics in the fourth quarter worth about $25,300,000. Ameritas Advisory Services LLC bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $381,000. Finally, World Investment Advisors bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $674,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $67.12 on Friday. The company has a market capitalization of $7.96 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The company has a quick ratio of 3.66, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The firm has a 50 day moving average of $65.65 and a 200 day moving average of $68.64. Halozyme Therapeutics, Inc. has a twelve month low of $48.64 and a twelve month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, COO Cortney Caudill sold 8,857 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares in the company, valued at approximately $477,200.20. This trade represents a 55.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the sale, the director directly owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. This trade represents a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,482 shares of company stock valued at $8,200,842 over the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of a number of analyst reports. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Finally, Benchmark raised their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $80.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.